Faculty, Staff and Student Publications
Language
English
Publication Date
1-1-2026
Journal
Cureus
DOI
10.7759/cureus.101086
PMID
41658810
PMCID
PMC12882740
PubMedCentral® Posted Date
1-8-2026
PubMedCentral® Full Text Version
Post-print
Abstract
Indolent systemic mastocytosis (ISM) is a clonal mast cell disorder characterized by recurrent symptoms that can persist despite treatment with antihistamines, leukotriene antagonists, and mast cell stabilizers. Treatment options are limited when symptoms remain refractory, and avapritinib is contraindicated or declined. We describe the case of a 62-year-old female with an 11-year history of ISM who developed worsening pruritus and urticaria despite extensive conservative and biologic therapies, including topical corticosteroids, hydroxyzine, montelukast, omalizumab, and dupilumab. Given her history of stroke, she declined avapritinib. Nemolizumab was initiated with a 60 mg loading dose followed by 30 mg every four weeks. After 12 doses, she achieved complete resolution of pruritus. This report suggests that nemolizumab may represent a potential therapeutic option for refractory ISM when standard therapies fail or targeted KIT inhibition is not feasible.
Keywords
anti-il-31 therapy, indolent systemic mastocytosis, mast cell disease, nemolizumab, systemic mastocytosis, systemic mastocytosis therapy
Published Open-Access
yes
Recommended Citation
Sezim Minbaeva and Stephen K Tyring, "Nemolizumab as an Alternative Therapeutic Option for Indolent Systemic Mastocytosis" (2026). Faculty, Staff and Student Publications. 3442.
https://digitalcommons.library.tmc.edu/uthmed_docs/3442